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Abstract
Background:  Hepatitis C virus (HCV) is a significant problem for patients undergoing
hemodialysis therapy. This situation has never been studied in Mato Grosso state, central Brazil.
This study was conducted aiming to estimate the prevalence of the anti-HCV and the incidence of
seroconversion in the main metropolitan region of the state.
Methods: 433 patients from the six hemodialysis units were interviewed and anti-HCV was tested
by a third-generation enzyme immunoassay. An open cohort of patients who tested negative for
anti-HCV at the entry of the study was created and seroconversions was assessed monthly. The
staff responsible for the units were interviewed to assess whether the infection control measures
were being followed. Logistic and Cox regression analysis were performed in order to assess risk
factor to HCV.
Results: The entry on the study took place between January 2002 and June 2005. 73 out of 433
(16.9%, CI95%: 13.3–20.8) was found to be anti-HCV reactive. The multivariate analysis indicated
as risk factors associated to anti-HCV the duration of the hemodialysis treatment, the number of
transfusions received, and the unit of treatment. An open cohort of 360 patients who tested
negative for anti-HCV was created, with a following average of 24 (± 15) months. Forty
seroconversions were recorded corresponding to an incidence density of 4.6/1000 patient-months,
ranges 0 to 30 among the units. Cox regression indicated the time of hemodialysis (RR = 2.2;
CI95%: 1.1–4.6; p < 0.05) and the unit where treatment was performed (RR = 42.4; CI95%: 9.9–
180.5; p < 0.05) as risk factors for seroconversion. The three units with highest anti-HCV
prevalence and incidence were identified as those that more frequently failed to apply control
measures.
Conclusion: The study demonstrated high prevalence and incidence of anti-HCV in some of the
hemodialysis units. Time on hemodialysis therapy was an independent factor associated to HCV.
Blood transfusion was associated with anti-HCV in initial survey but was not important in incident
cases. Failure of applying control meaures was more evident in units with the highest HCV
prevalence and incidence. The results suggest that nosocomial transmission was the main spread
factor of HCV in the studied population.
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Background
Hepatitis C Virus (HCV) infection is a common cause of
chronic liver disease worldwide [1-3]. This virus is effi-
ciently transmitted by parenteral route. As a consequence
people sharing needles and syringes or submitted to
blood transfusion and frequent vascular puncture espe-
cially on nosocomial environment are under increased
risk. Antibodies against HCV (anti-HCV) reach high prev-
alence among chronic renal failure patients undergoing
hemodialysis, and it is responsible for an increase in
hepatic mortality and morbidity in this population [4-7].
In the past, transmission of HCV in patients undergoing
hemodialysis was associated with blood transfusions,
which were often necessary [8-11]. However, even with
the increase in the safety of blood products and the
decrease in the need for transfusions in this population,
the HCV was proven to still circulate among patients
undergoing hemodialysis by ways other than transfusions
[12-15]. As a consequence, several prophylactic measures
have been suggested to avoid infection by HCV in the
hemodialysis environment, from isolating the patients
carriers of HCV [15-18], to adopting a series of biosafety
measures specific for hemodialysis such as preparing
medications in a separated area, cleaning and disinfecting
dialysis station surfaces, washing hands and changing
gloves between patient contacts, and items dedicated for
use only on a single patient [3,14,19,20].
International studies in hemodialysis patients have
reported HCV seroprevalence rates ranging from 2.6% in
Japan to 30.0% in Italy [2,21]. In Brazil, prevalence rates
were reported to range from 11% to 90%, in hemodialysis
units in different cities throughout the country
[4,8,12,22,23].
It is important to know the prevalence and incidence of
infection by HCV in local hemodialysis units so that
changes can be proposed and the risks of infection among
patients can be assessed. This situation has never been sys-
tematically studied in the state of Mato Grosso, in the cen-
tral region of Brazil. The aim of this study was to estimate
the prevalence and the rate of seroconversion to anti-
HCV, and identify possible risk factors for patients in all
hemodialysis units in the metropolitan area of the capital
of the state of Mato Grosso.
Methods
Data were collected on chronic renal failure patients that
had been undergoing hemodialysis treatment for at least
one month, at all units that provide renal facilities in the
metropolitan area of Cuiabá, Mato Grosso, from January
2002 to June 2005. The great majority of patients were
dependent of Brazilian Public Healthcare System.
Information on the patient and their medical records was
collected, regarding the risk of transmission of HCV, such
as the duration of the hemodialysis treatment, the
number of transfusions received, the use of injectable
drugs, the number of hemodialysis units visited, and sex-
ual habits. The nurses responsible for the staff at the stud-
ied clinics were interviewed in order to assess whether the
prevention measures recommended by the US Center for
Disease Control and Prevention were being followed.
Serologic tests for detection of anti-HCV were performed
monthly using third generation microparticle enzyme
immunoassays (MEIA) (Axsym® HCV, version 3.0, Abbott,
Wiesbaden, Germany). All patients confirmed to carry
anti-HCV by repeated tests on new blood samples were
considered positive.
The anti-HCV results were assessed starting in January
2002, for patients that had already been undergoing
hemodialysis treatment, as well as those patients who
started their treatment in the subsequent months, up to
June 2005. The monthly results of these tests were com-
puted so as to create an open cohort of anti-HCV negative
patients that allowed an analysis of the risk of infection by
HCV during the study.
All anti-HCV positive patients were referred to hepatology
service. Permission to conduct the study was obtained
from the technical directors of each one of the six clinics
involved. The patients who agreed to participate in the
study signed consent forms stating that they were doing so
freely. The protocol for the study was approved by the
Committee of Ethics for Research on Human Beings of the
University of Cuiabá – UNIC (protocol No. 003/04).
The data obtained were stored using the software EpiData®
3.0 (The EpiData Association, Odense, Denmark, 2003).
A transverse analysis was performed on the results of the
first laboratory assessment of anti-HCV on the partici-
pants, comparing the confirmed anti-HCV-positive
patients with the group of anti-HCV-negative patients.
Appropriated statistical tests were performed to compare
continuous and categoric variables, with respective disper-
sion and confidence interval of 95% (CI95%), using the
software EpiInfo 2002 (Centers for Disease Control and Pre-
vention, Atlanta, US).
A logistic regression model was created to analyze the
association of positive anti-HCV with the co-variables
associated in the univariate analysis, at an alpha error rate
of less than 0.1. For this analysis, a non-automated
method was used, with the help of the software SPSS 13.0
for Windows (SPSS INC., Chicago, US, 2004).BMC Public Health 2007, 7:32 http://www.biomedcentral.com/1471-2458/7/32
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For the analysis of the cohort of patients who initially
tested negative for anti-HCV, probability curves for sero-
conversion over time were created using the Kaplan-Meier
method, as well as Cox regression models to adjust the
variables of interest in SPSS 13.0. Hazard risks (HR) were
presented with their respective CI95%.
Results
The results from 433 individuals undergoing hemodialy-
sis in the six clinics studied were analyzed, admitted into
the study from January 2002 to May 2005. The average
duration of hemodialysis treatment after admission in the
study was 43 months (± 36.3), varying from 1 to 204
months. The majority of the patients (84.1%) had already
received transfusion of at least one unit of blood deriva-
tive product.
Of the 433 patients evaluated, 73 were anti-HCV positive,
which represented prevalence in the period analyzed of
16.9% (CI95%: 13.3%–20.8%). Variation among clinics
was 6.2% to 37.8%. Patient characteristics are shown on
Table 1.
All clinics routinely restricted anti-HCV-positive patients
to machines that were kept specifically for patients with
this condition. The individual dialysis devices (capillar-
ies) were reprocessed in separate rooms.
Table 2 shows the assessed data on infection control
measures for the six studied hemodialysis units. The three
units with highest anti-HCV prevalence and incidence
were identified as those that more frequently failed to
apply control measures. For the multivariate analyses, the
patients were classified into two groups of clinics: group A
(4, 5, 6 units), with better adherence to control measures
and group B (1, 2, 3 units), with poor adherence. Anti-
HCV positivity showed an independent association with
the duration of the hemodialysis treatment (p < 0.001),
patients having received more than six units of blood
products (p < 0.005) and belonging to one of the clinics
in group B (p < 0.001) (Table 3). Risk factor classically
associated with HCV transmission such as illicit drug
abuse and promiscuous sexual behaviour were seldom
reported by participants and did not show association
with anti-HCV positivity. Previous surgical procedures
were also not associate to anti-HCV.
The 360 patients who were anti-HCV negative in the first
evaluation comprised an open cohort in which the anti-
HCV results were assessed monthly. In June 2005, the
patients who were still being studied and who had not
shown seroconversion of anti-HCV were censored. The
segment lasted in average 24 ± 15 months.
During the segment, 40 cases of seroconversion of anti-
HCV were recorded, which were irregularly distributed
among the clinics. The incidence rates varied between 0
Table 1: Epidemiologic characteristics of patients undergoing hemodialysis treatment at entry of the study, per unit
Hemodialysis Units
123456 T o t a l
P a t i e n t s 1 1 6 3 75 88 57 26 5 4 3 3
Sex Male (%) 60.3 59.5 63.8 64.7 63.9 52.3 61
Age (m ± sd)* 48 (15) 50 (16) 49 (15) 49 (15) 49 (15) 55 (14) 50 (15)
Transfusion (%) 81.9 89.2 82.8 90.6 79.2 83.1 84.1
No. transf. (%)**
1 – 2 36.5 36.4 54.2 33.8 45.6 47.2 41.2
3 – 6 40.6 36.4 29.2 37.7 26.3 34.0 34.9
> 6 22.9 27.3 16.7 28.6 28.1 18.9 23.9
Duration HD*** (m ± sd) 41 ± 36 60 ± 35 37 ± 34 55 ± 41 33 ± 29 39 ± 34 43 ± 36
> 1 clinic visited (%) 11.2 67.6 51.7 37.6 29.2 56.9 36.5
DST (%) 15.5 24.3 31.0 31.8 26.8 26.2 25.0
Anti-HCV 24.1 37.8 17.2 12.9 8.3 6.2 16.9
CI95 (%) 16–33 22–55 9–29 7–22 3–17 2–15 13–21
*m ± sd: mean ± standard deviation;
** No. transf: number of transfusions received;
***Duration HD: duration in months of the hemodialysis treatment.BMC Public Health 2007, 7:32 http://www.biomedcentral.com/1471-2458/7/32
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and 30.5 cases/1000 patient-months (Table 4). The prob-
ability curve for seroconversion for the set of patients is
shown in Figure 1. Figure 2 shows the probability curve
for seroconversion, comparing groups A and B.
The multivariate analysis of the cohort, adjusted for the
variables of age group, gender, and number of transfu-
sions, demonstrated that belonging to the clinics in group
B represented a relative risk nine times higher (HR: 42.4;
CI95%: 9.9%–180.5%). In addition, only the variable of
having received hemodialysis treatment for more than
four years at the beginning of the study showed a signifi-
cant association, with a relative risk of 2.2 (CI95%: 1.1%–
4.6%) (Table 5).
Discussion
This article represents the first seroepidemiologic study on
HCV spread among patients undergoing hemodialysis in
the state of Mato Grosso, Brazil. The prevalence of anti-
bodies to HCV in our sample was similar to that found in
the United States, Japan, and other Brazilian states, but
lower than that found by Carneiro et al. (2001) in Goi-
ania, that is a large city also located in the central region
of Brazil 900 Km apart from the region of the present
study [2,4,22,23]
However, in our study, in three units (1, 2, and 3) that
failed to adopt all internationally standardized infection
control measures, we found higher HCV prevalence and
Table 3: Risk factor associated with the initial prevalence of HCV seropositivity at the six hemodialysis clinics
Risk Factors N (%) Anti-HCV + (%) OR* adjusted (CI95%) p
Duration HD*
Up to 4 years 278 (64.2) 9 (3.2) 1 -
Over 4 years 155 (35.8) 64 (41.3) 21.5 (9.7–47.6) 0.000
No. transfusions
1 – 2 150 (41.2) 20 (13.3) 1 -
3 – 6 127 (34.9) 23 (18.1) 3.8 (0.9–15.8) 0.068
> 6 87 (23.9) 27 (31.0) 4.4 (1.0–18.6) 0.045
Clinic groups
A (4,5,6) 222 (51.3) 21 (9.4) 1 -
B (1,2,3) 211 (48.7) 52 (24.6) 4.9 (2.5–9.6) 0.000
*OR = odds ratio. ** Duration HD: duration of hemodialysis treatment. Multivariate analysis adjusted by transfusion, age group, and gender.
Table 2: Evaluation of infection control practices of each hemodialysis units
Units
Control measures Group B Group A
12 3 4 5 6
Dedicated machines + + + + + +
Wear and change disposable gloves - - - + + +
Clean and disinfect the hemodialysis station + - - + + +
Individual supplies and dedicated staff - - - + + +
Cleaning and disinfection of equipments - + - + + +
Clean area to prepare medications - - - - + +
Prevalence (CI95%) 24 (16–33) 38 (22–55) 17 (9–29) 13 (7–22) 8 (3–17) 6 (2–15)
Incidence rates (CI95%) 7.7 (3.9–11.4) 30.5 (13.3–47.8) 13 (5–21) 0 0.6 (0–1.9) 0.6 (0–1.8)BMC Public Health 2007, 7:32 http://www.biomedcentral.com/1471-2458/7/32
Page 5 of 8
(page number not for citation purposes)
incidence rates. Particularly in these three units items were
likely shared among patients, clean and disinfection of
equipments were insufficient, and a policy of glove use
and handwashing was lacking. Similar findings were evi-
denced in other studies on hemodialysis units analysed in
other large Brazilian cities [4,8,11]. Moreover, as already
reported [21] higher HCV incidence rates were associated
with a high burden of HCV positive patients treated in the
same unit. It is likely that also understaffing [21], not
studied in our report, played a role in the spread of HCV
infection among patients undergoing dialysis in units
with high HCV prevalence rates.
Additionally, higher incidence rates occurred in those
units were a break of infection control measures was evi-
dent. This further suggests that improper practices and
environmental infection control breaks, more than the
blood transfusion, may represent the major factors in the
HCV transmission among hemodialysis patients [12-14].
The number of transfusions received up until admission
into the study was associated with higher HCV prevalence
rates, but not with the frequency of new HCV seroconver-
sions. Patients who had received transfusions before
entering the study could have been exposed to HCV if they
received theses transfusions before the blood banks
started testing for anti-HCV and when the serologic meth-
ods were less sensitive. Moreover, as reported by several
authors [24-28] in our study the duration of the hemodi-
alysis treatment was associated with HCV acquisition,
thus suggesting a nosocomial route of transmission of
HCV infection.
Another interesting point raised by our study, was the lack
of association between isolation of HCV infected patients,
adopted in all the units, and lower HCV incidence rates.
Indeed, high incidence rates were independent from iso-
lation policies and were associated with a break in infec-
tion control measures, including lack of glove exchange
between patients, handwashing, cleaning, and disinfec-
tion.
The follow up of initially anti-HCV-negative individuals
revealed 40 seroconversions. It corresponds to a cumula-
tive incidence ranging from 0 to 30.5/1000 patient-
months by units. These new infections were evidently
more frequent at the clinics that had a higher anti-HCV
prevalence and failure in infection control measures.
Blood transfusions were not more frequent among these
new infected patients than anti-HCV-negative subjects.
These aspects reinforces the impression that the environ-
ment, more than the blood transfusion and other risk fac-
tors, may have been the determining factor in the
transmission of HCV among hemodialysis patients
[15,22,27].
There was a lack of association between anti-HCV positiv-
ity and having received hemodialysis treatment in differ-
Table 4: Density incidence of anti-HCV seroconversion per hemodialysis clinic between 2002 and 2005
Clinic No. patients studied Follow up average (months) No. of events Events/1000 patient-months (CI95%)
1 88 24 16 7.7 (3.9 – 11.4)
2 23 17 12 30.5 (13.3 – 47.8)
3 48 16 10 13 (5 – 21)
47 4 3 0 0 0
5 66 24 1 0.6 (0 – 1.9)
6 61 27 1 0.6 (0 – 1.8)
Total 360 24 40 4.6 (3.2 – 6.1)
Probability curve for seroconversion to anti-HCV as a func- tion of time, patients undergoing hemodialysis treatment Figure 1
Probability curve for seroconversion to anti-HCV as a func-
tion of time, patients undergoing hemodialysis treatment.
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ent units, a factor appointed as important by others
authors, [21,22,25]. This aspect was not verified in the
present study, maybe because this factor was not frequent
among our sampled patients.
Our study has some limitations. First, we did not perform
assays for HCV-RNA, by using polimerase chain reaction
(PCR). This method permits to evidence HCV infected
individuals without antibodies to HCV, a condition that
involves approximately up to 5% of patients in the hemo-
dialysis setting [29]. However, this method is still expen-
sive to be performed as a screening test in most of
developing countries. In Brazil, immunoenzymatic assays
(EIA) are routinely employed in blood banks and hemo-
dialysis units to search for HCV-infected patients.
Although anti-HCV positivity by EIA does not discrimi-
nate between patients with HCV viremia and those who
had HCV cleared, it is very sensitive and may occasionally
identify hemodialysis patients with very low viremia not
detected by PCR. Aiming to increase EIA specificity only
successively positive anti-HCV patients were considered as
a case in the present study. Furthermore, the positive pre-
dict value of anti-HCV by EIA increases in high prevalence
settings such as hemodialysis environment. Some of the
anti-HCV positive patients detected in the first evaluation
could have already had the HCV cleared. Since our goal
was assessing prevalence of infection instead of viremia,
EIA may be likewise useful.
Second, we did not studied some likely involved in HCV
in hemodialysis settings, such as having been submitted
to surgical interventions on previous months [21].
In conclusion, the lesson from our study is that imple-
mentation of a isolation policy for patients with antibod-
ies to HCV is insufficient to prevent new HCV infections
when infection control measures are lacking, especially in
units with a high burden of HCV infection and, likely,
understaffing. In addition, isolation does not prevent
superinfections by other HCV genotypes circulating the
hemodialysis setting [30].
Local public health authorities were alerted about these
results in order to implement a surveillance system and
retraining units personnel on recommended infection
control measures in hemodialysis units.
Conclusion
High prevalence and incidence of anti-HCV were shown
in some of the hemodialysis units in Mato Grosso state,
Central Brazil. Time on hemodialysis therapy was an inde-
pendent factor associated to HCV. Blood transfusion was
associated with anti-HCV in initial survey but was not
important in incident cases. These findings suggest that
nosocomial transmission assumed a pivotal role for the
Table 5: Cox regression analysis to assess risk of anti-HCV seroconversion in patients undergoing hemodialysis therapy*
Risk Factors N (%) Anti-HCV + (%) Adjusted Hazard Ratio (CI95%) P
Time on HDT*
Up to 4 years 269 (74.7) 25 (62.5) 1 -
> 4 years 91 (25.3) 15 (37.5) 2.2 (1.1–4.6) 0.027
Unit Groups
A (4,5,6) 201 (55.8) 2 (5) 1 -
B (1,2,3) 159 (44.2) 38 (95) 42.4 (9.9–180.5) 0.000
*Adjusted by transfusion, number of transfusions, age group, and gender.
**HDT: hemodialysis therapy.
Probability curve for seroconversion to anti-HCV as a func- tion of time, stratified by groups of clinics (A: continuous line,  B: hatched line) Figure 2
Probability curve for seroconversion to anti-HCV as a func-
tion of time, stratified by groups of clinics (A: continuous line, 
B: hatched line). Log Rank (Mantel-Cox): χ2 = 59.3; p = 
0.0001. Degree of freedom = 1.
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HCV circulation occurring throughout the follow up
period. Failure of applying control measures was more
evident in units with the highest HCV prevalence and inci-
dence, reinforcing that nosocomial transmission was the
main spread factor of HCV in the studied population.
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